9 results on '"Montoro, J"'
Search Results
2. Post-transfusion purpura as the main manifestation of a trilineal transfusion reaction, responsive to steroids: flow-cytometric investigation of granulocyte and platelet antibodies
- Author
-
Puig, N., Sayas, M. J., Montoro, J. A., Villalba, J. V., and Pla, A.
- Published
- 1991
- Full Text
- View/download PDF
3. Posttransplant monomorphic Burkitt's lymphoma: clinical characteristics and outcome of a multicenter series.
- Author
-
on behalf of the Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL/TAMO cooperative group), Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL/TAMO cooperative group), Bobillo, S., Abrisqueta, P., Montoro, J., López, A., Bosch, F., Bento, L., Montes, S., Sánchez-González, B., Giné, E., Romero, S., Alcoceba, M., González-Barca, E., González de Villambrosía, S., Sancho, J. M., and Gómez, P.
- Subjects
ANTINEOPLASTIC agents ,B cell lymphoma ,COMPARATIVE studies ,DOXORUBICIN ,EPSTEIN-Barr virus ,HEMATOPOIETIC stem cell transplantation ,HOMOGRAFTS ,RESEARCH methodology ,MEDICAL cooperation ,MONOCLONAL antibodies ,PREDNISONE ,PROGNOSIS ,RESEARCH ,SURVIVAL ,TRANSPLANTATION of organs, tissues, etc. ,VINCRISTINE ,EVALUATION research ,CYCLOPHOSPHAMIDE - Abstract
Burkitt's monomorphic posttransplant lymphoproliferative disorder (B-PTLD) is an uncommon subtype of PTLD. Owing to the paucity of this complication, clinical characteristics and outcome has not been fully described. Clinical characteristics and outcomes of 20 patients diagnosed with B-PTLD from 10 transplant centers belonging to the GEL/TAMO group were reviewed. Median time from transplant to B-PTLD was 7.2 years. All the cases fulfill the morphologic and genetic criteria of B-PTLD, whereas Epstein-Barr virus (EBV) was detected in 70% of cases. Patients were treated with different chemotherapy combinations, and three patients received upfront rituximab monotherapy. The great majority of patients receiving CHOP-like regimens attained a complete response (CR) (73%), similar to that obtained with dose-intensive chemotherapy (83% CR). In contrast, patients receiving upfront rituximab monotherapy required subsequent chemotherapy. Two patients (10%) died during treatment due to infection. The median progression-free survival and overall survival (OS) were 16 months and 139 months, respectively. When analyzing variables predicting for OS, we found that patients with bone marrow involvement had an adverse prognosis, with a median OS of 6 months (p = 0.008). In conclusion, B-PTLD is an uncommon complication usually associated with EBV infection and with an aggressive clinical course, particularly in patients with bone marrow involvement. High-dose chemoimmunotherapy obtained similar responses to R-CHOP, suggesting that R-CHOP could be an adequate alternative for these patients. In contrast, rituximab monotherapy does not seem to be effective enough to control the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
4. Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies.
- Author
-
Cordón L, Chorão P, Martín-Herreros B, Montoro J, Balaguer A, Guerreiro M, Villalba M, Facal A, Asensi P, Solves P, Gómez I, Santiago M, Lamas B, Bataller A, Granados P, Sempere A, Sanz GF, Sanz MA, and Sanz J
- Subjects
- Humans, Female, Male, Adult, Middle Aged, Aged, Young Adult, Adolescent, Killer Cells, Natural immunology, Myeloablative Agonists therapeutic use, Transplantation Conditioning methods, Hematologic Neoplasms therapy, Cord Blood Stem Cell Transplantation methods, Antilymphocyte Serum therapeutic use, Graft vs Host Disease etiology, Graft vs Host Disease prevention & control, Immune Reconstitution
- Abstract
This study aimed to investigate the kinetics of immune recovery following umbilical cord blood transplantation (UCBT) in adults who received a myeloablative conditioning (MAC) regimen and antithymocyte globulin (ATG). While the immune recovery kinetics has been extensively studied in pediatric UCBT recipients, limited data exist for adults. We conducted a comprehensive analysis of 221 consecutive adult patients who underwent UCBT with MAC and ATG at a single institution. Our objective was to evaluate the influence of patient, disease, and transplant factors, along with acute graft-versus-host disease (aGVHD), on immune reconstitution and overall survival. Our findings confirm a delayed recovery of T cells, while B and NK cell reconstitution exhibited rapid progress, with NK cell counts reaching normal levels within 3 months post-transplantation and B cells within 6 months. Within CD3
+ T cells, CD8+ T cells also experienced a delayed recovery (12 months), but to a lesser extent compared to CD4+ T cells (18 months). Delayed immune recovery of T-cell subsets was associated with the development of aGVHD grade II-IV, older age, CMV negativity, and a female donor. Patients with lymphoproliferative diseases showed slower NK cell recovery. Our study demonstrates that adult patients undergoing MAC with ATG and receiving a single unit UCBT for hematologic malignancies experienced rapid reconstitution of NK and B cells. However, T cell recovery, particularly CD4+ T cells, was significantly delayed. To enhance T cell recovery, it may be crucial to consider UCB units with higher cellularity and optimize ATG doses in conditioning., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)- Published
- 2024
- Full Text
- View/download PDF
5. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients.
- Author
-
Piñana JL, Rodríguez-Belenguer P, Caballero D, Martino R, Lopez-Corral L, Terol MJ, Vazquez L, Calabuig M, Sanz-Linares G, Marin-Jimenez F, Alonso C, Montoro J, Ferrer E, Facal A, Pascual MJ, Rodriguez-Fernandez A, Olave MT, Cascales-Hernandez A, Gago B, Hernández-Rivas JÁ, Villalon L, Corona M, Roldán-Pérez A, Ribes-Amoros J, González-Santillana C, Garcia-Sanz R, Navarro D, Serrano-López AJ, Cedillo Á, Soria-Olivas E, Sureda A, and Solano C
- Subjects
- Antibodies, Monoclonal, Antibodies, Viral, BNT162 Vaccine, COVID-19 Vaccines, Early Detection of Cancer, Humans, SARS-CoV-2, Vaccination, Antineoplastic Agents, COVID-19 diagnosis, COVID-19 prevention & control
- Abstract
Prior studies of antibody response after full SARS-CoV-2 vaccination in hematological patients have confirmed lower antibody levels compared to the general population. Serological response in hematological patients varies widely according to the disease type and its status, and the treatment given and its timing with respect to vaccination. Through probabilistic machine learning graphical models, we estimated the conditional probabilities of having detectable anti-SARS-CoV-2 antibodies at 3-6 weeks after SARS-CoV-2 vaccination in a large cohort of patients with several hematological diseases (n= 1166). Most patients received mRNA-based vaccines (97%), mainly Moderna® mRNA-1273 (74%) followed by Pfizer-BioNTech® BNT162b2 (23%). The overall antibody detection rate at 3 to 6 weeks after full vaccination for the entire cohort was 79%. Variables such as type of disease, timing of anti-CD20 monoclonal antibody therapy, age, corticosteroids therapy, vaccine type, disease status, or prior infection with SARS-CoV-2 are among the most relevant conditions influencing SARS-CoV-2-IgG-reactive antibody detection. A lower probability of having detectable antibodies was observed in patients with B-cell non-Hodgkin's lymphoma treated with anti-CD20 monoclonal antibodies within 6 months before vaccination (29.32%), whereas the highest probability was observed in younger patients with chronic myeloproliferative neoplasms (99.53%). The Moderna® mRNA-1273 compound provided higher probabilities of antibody detection in all scenarios. This study depicts conditional probabilities of having detectable antibodies in the whole cohort and in specific scenarios such as B cell NHL, CLL, MM, and cMPN that may impact humoral responses. These results could be useful to focus on additional preventive and/or monitoring interventions in these highly immunosuppressed hematological patients., (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
6. Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation.
- Author
-
Bailén R, Kwon M, Pascual-Cascón MJ, Ferrà C, Sanz J, Gallardo-Morillo A, García-Sola A, Torrent A, Jiménez-Lorenzo MJ, Piñana JL, Montoro J, Oarbeascoa G, Dorado N, Gómez-Centurión I, Muñoz C, Martínez-Laperche C, Anguita J, Buño I, and Díez-Martín JL
- Subjects
- Adolescent, Adult, Aged, Allografts, Disease-Free Survival, Female, Follow-Up Studies, Humans, Incidence, Male, Middle Aged, Retrospective Studies, Survival Rate, Antilymphocyte Serum administration & dosage, Cyclophosphamide administration & dosage, Graft vs Host Disease mortality, Graft vs Host Disease prevention & control, Peripheral Blood Stem Cell Transplantation, Unrelated Donors
- Abstract
Post-transplant cyclophosphamide (PTCY) effectively prevents graft-versus-host disease after unmanipulated HLA-haploidentical HSCT. The use of PTCY in the unrelated donor HSCT setting is less explored. We conducted a retrospective study of 132 consecutive patients undergoing a matched or 9/10 mismatched unrelated donor HSCT in 4 centers in Spain, 60 with anti-thymocyte globulin (ATG)-based prophylaxis combined with MTX-CsA, and 72 using a PTCY-based regimen. Peripheral blood stem cells were used as graft in most patients (111 patients, 84%); mMUD donors were balanced between groups. Cumulative incidences of grades II-IV and III-IV acute GVHD at 100 days were lower in the PTCy group (46% vs. 67%, p = 0.008; 3% vs. 34%, p = 0.003), without statistically significant differences in the 2-year cumulative incidence of chronic moderate-severe GVHD. At 2 years, no significant differences were observed in overall survival, event-free survival, cumulative incidence of relapse, and non-relapse mortality. GVHD was the most frequent cause of NRM in the ATG group. No differences were observed between groups in the composite endpoint of GVHD-free and relapse-free survival. In this study, PTCy combined with additional immunosuppression after MUD/mMUD HSCT showed a reduction of aGVHD rate with safety results comparable to those obtained with the ATG-based prophylaxis.
- Published
- 2021
- Full Text
- View/download PDF
7. Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes.
- Author
-
Montoro J, Gallur L, Merchán B, Molero A, Roldán E, Martínez-Valle F, Villacampa G, Navarrete M, Ortega M, Castellví J, Saumell S, Bobillo S, Bosch F, and Valcárcel D
- Subjects
- Adult, Aged, Aged, 80 and over, Autoimmune Diseases diagnosis, Autoimmune Diseases epidemiology, Autoimmune Diseases immunology, Biomarkers, Female, Humans, Incidence, Leukemia, Myelomonocytic, Chronic epidemiology, Leukemia, Myelomonocytic, Chronic etiology, Male, Middle Aged, Myelodysplastic Syndromes diagnosis, Patient Outcome Assessment, Prevalence, Prognosis, Young Adult, Autoimmune Diseases complications, Myelodysplastic Syndromes complications, Myelodysplastic Syndromes epidemiology
- Abstract
The coexistence of autoimmune disorders (AD) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) has been widely recognized, although with distinct results regarding their prevalence and impact on the outcomes of the underlying hematological process. This study was aimed to analyze the prevalence, clinical characteristics, and outcomes of MDS with AD in a series of 142 patients diagnosed with MDS and CMML. AD was ascertained by both the presence of clinical symptoms or compatible serological tests. In total, 48% patients were diagnosed as having AD, being hypothyroidism the most commonly reported clinical AD (8%) and antinuclear antibodies the most frequent serological parameter identified (23.2%). The presence of AD was associated with female gender, lower hemoglobin levels, and higher IPSS-R. Overall survival for patients with AD was inferior to those with no AD (69 vs. 88% at 30 months; HR 2.75, P = 0.008). Notably, clinical but not isolated immune serological parameters had an impact on the outcomes of patients with AD. Finally, in a multivariate analysis, the presence of AD (HR 2.26) along with disease risk categories (very low and low vs. intermediate, high, and very high IPSS-R; HR 4.62) retained their independent prognostic value (P < 0.001). In conclusion, AD are prevalent in MDS and CMML patients and have prognostic implications, especially in lower-risk MDS patients.
- Published
- 2018
- Full Text
- View/download PDF
8. Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation.
- Author
-
Solves P, Sanz J, Freiria C, Santiago M, Villalba A, Gómez I, Montesinos P, Montoro J, Piñana JL, Lorenzo JI, Puig N, Sanz GF, Sanz MÁ, and Carpio N
- Subjects
- Adolescent, Adult, Aged, Female, Graft Rejection epidemiology, Graft Rejection mortality, Hematologic Neoplasms mortality, Hematopoietic Stem Cell Transplantation adverse effects, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Survival Analysis, Transplantation, Homologous, Treatment Failure, Young Adult, Graft Rejection etiology, Hematologic Neoplasms therapy, Hematopoietic Stem Cell Transplantation methods, Platelet Transfusion mortality, Platelet Transfusion statistics & numerical data
- Abstract
Hematopoietic stem cell transplantation has been considered a risk factor for development of platelet transfusion refractoriness. The objective of this study was to assess the platelet transfusion refractoriness rate in patients undergoing allogeneic hematopoietic stem cell transplantation from different sources. We retrospectively reviewed the charts and transfusion records of patients who underwent allogeneic stem cell transplantation at our institution between 2013 and 2015. The evaluation of post-transfusion platelet count was assessed for each transfusion given, from day of progenitor infusion to day 30 after transplantation. Of 167 patients included in this study, 101 received peripheral blood stem cell transplantation (PBSCT) and 66 received umbilical cord blood transplantation (UCBT). Overall, the percentage of platelet transfusions with a 14-h CCI lower than 5000 was 59.3%, being these data significantly higher for UCBT (67.6%) than for PBSCT (31.0%). Seventy-eight percent of patients underwent UCBT become refractory, while 38.6% of patients who received PBSCT were refractory. Factors associated to platelet refractoriness were lower CD34+ cell dose infused, higher number of antibiotics used, presence of anti-HLA I antibodies, and reduced-intensity conditioning regimen. Platelet refractoriness is a frequent and complex adverse event and remains a therapeutic challenge in the management of patients undergoing HSCT. There is a higher rate of platelet refractoriness in patients who received UCBT as compared to patients who received PBSCT.
- Published
- 2018
- Full Text
- View/download PDF
9. Calreticulin mutations are exceedingly rare in patients with myelodysplastic syndromes with myelofibrosis.
- Author
-
Montoro J, Robledo C, Zamora L, Valcárcel D, and Ramos F
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Myelodysplastic Syndromes diagnosis, Primary Myelofibrosis diagnosis, Calreticulin genetics, Mutation genetics, Myelodysplastic Syndromes genetics, Primary Myelofibrosis genetics
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.